Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Epidemiology 2: Epidemiology of Breast and Prostate Cancer

Benign breast disease and breast cancer risk

Lynn C. Hartmann, Daniel Visscher, Marlene H. Frost, Lee J. Melton III, Celine Vachon, Fergus Couch, Vijayalakshmi Shridhar, Karthik Ghosh, Amy Degnim, David Hillman, Vera Suman, Robert A. Vierkant, Shaun D. Maloney, Vernon S. Pankratz, Thea Tlsty, Thomas A. Sellers and Wilma L. Lingle
Lynn C. Hartmann
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Visscher
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marlene H. Frost
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee J. Melton
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celine Vachon
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fergus Couch
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vijayalakshmi Shridhar
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karthik Ghosh
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Degnim
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Hillman
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vera Suman
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Vierkant
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaun D. Maloney
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vernon S. Pankratz
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thea Tlsty
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas A. Sellers
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilma L. Lingle
Mayo Clinic Cancer Center, Rochester, MN, University of California, San Francisco, CA, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2004
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 45, 2004

Abstract

1089

Introduction: Benign breast disease (BBD) is an established risk factor for breast cancer (BC), but only a minority of women with BBD ultimately develop BC. To identify the subset of women at greatest risk for breast cancer at the time of BBD diagnosis, we have established a large historical cohort of women with BBD in which we can test more specific means of risk prediction, using clinical, histopathologic and molecular tools. Methods: The Mayo Clinic Surgical Index was used to identify all women ages 18-85 who had an open breast biopsy with benign findings at the Mayo Clinic between 1/1/67 and 12/31/91. The availability of tissue slides and blocks on these patients was verified through linkage to the Pathology Index. Medical record review was performed to verify eligibility and to identify subsequent occurrences of breast cancer diagnosed or treated at Mayo. A study-specific questionnaire is being used to collect risk factor data on the cohort and to identify breast cancers diagnosed outside of Mayo. Results: This 25-year cohort includes 11,782 women with 181,284 person years of follow-up. The median age at BBD diagnosis was 50.0 years. Some family history of BC was present in 40% of those surveyed; 21% had an affected first-degree relative. Thus far, 705 women are known to have developed BC, at a median of 9.2 years after their BBD. The interval from BBD to BC is 15 years, 23%. The cancer occurred in the same breast as the BBD in 279 women (40%), the opposite breast in 189 (27%) and both breasts in 18 (3%). Side is pending for 219 (31%). The estimated 5-yr, 10-yr and 15-yr BC incidence rates are 2.0%, 4.1%, and 6.4%, respectively for women with BBD from 1982-1991 (follow-up ongoing for 1967-81 group). The histopathologic review has been completed for 3,004 of the BBD specimens. Non-proliferative disease was found in 65.8%, proliferative disease without atypia in 28.6% and atypia (atypial ductal hyperplasia or atypial lobular hyperplasia) in 3%. Incorporating time from BBD to BC, histology, and side of BBD vs BC, we are exploring a panel of biomarkers as indicators of possible BC precursors or a background field change. Conclusions: We have assembled a large cohort of patients with BBD with extensive follow-up for breast cancer, excellent participation on a risk factor survey, and sufficient quantities of well-characterized tissues to permit independent evaluation of established and novel molecular markers. Supported by grants from the national Komen Foundation, the Breast Cancer Research Foundation, and DOD Breast Cancer Center of Excellence award DAMD 17-02-1-0473.

  • American Association for Cancer Research
Previous
Back to top
April 2004
Volume 64, Issue 7 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Benign breast disease and breast cancer risk
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Benign breast disease and breast cancer risk
Lynn C. Hartmann, Daniel Visscher, Marlene H. Frost, Lee J. Melton III, Celine Vachon, Fergus Couch, Vijayalakshmi Shridhar, Karthik Ghosh, Amy Degnim, David Hillman, Vera Suman, Robert A. Vierkant, Shaun D. Maloney, Vernon S. Pankratz, Thea Tlsty, Thomas A. Sellers and Wilma L. Lingle
Cancer Res April 1 2004 (64) (7 Supplement) 248;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Benign breast disease and breast cancer risk
Lynn C. Hartmann, Daniel Visscher, Marlene H. Frost, Lee J. Melton III, Celine Vachon, Fergus Couch, Vijayalakshmi Shridhar, Karthik Ghosh, Amy Degnim, David Hillman, Vera Suman, Robert A. Vierkant, Shaun D. Maloney, Vernon S. Pankratz, Thea Tlsty, Thomas A. Sellers and Wilma L. Lingle
Cancer Res April 1 2004 (64) (7 Supplement) 248;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Finger pattern and prostate cancer risk: A case-control study using BPH and community-based population as controls
  • Dietary intake of conjugated linoleic acids and risk of pre- and postmenopausal breast cancer, Western New York Exposures and Breast Cancer Study (WEB Study)
  • Environmental variables and family history of breast cancer
Show more Epidemiology 2: Epidemiology of Breast and Prostate Cancer
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement